Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
In the paradigm of targeted therapy, “Diagnosis and Staging” undergoes a fundamental redefinition. While anatomical staging (TNM) remains relevant for prognosis, the critical determinant for treatment selection is the “Molecular Diagnosis.” This phase involves interrogating the tumor’s genome and proteome to identify specific targets that can be pharmacologically exploited. It is a process of companion diagnostics in which the diagnostic test is inextricably linked to the therapeutic agent. Without a positive biomarker result, the diagnosis is incomplete, and therapy cannot be administered.
The process begins with the acquisition of tumor tissue, but the analysis goes far beyond standard histology. The tissue is subjected to sophisticated molecular profiling technologies. Fluorescence In Situ Hybridization (FISH) is used to detect gene amplifications (like HER2) or translocations (like ALK or ROS1). Immunohistochemistry (IHC) measures the expression level of proteins on the cell surface. However, the gold standard in modern oncology is Next Generation Sequencing (NGS). NGS enables the simultaneous sequencing of hundreds of genes, identifying point mutations, insertions, deletions, and copy-number variations in a single run. This broad profiling is essential because many actionable mutations are rare and would be missed by single-gene testing.
A revolutionary advancement in diagnostic staging is the liquid biopsy. This technology analyzes circulating tumor DNA (ctDNA) shed by cancer cells into the bloodstream. It offers a non-invasive method to profile the tumor’s genetics without the need for a surgical procedure or invasive needle biopsy. Liquid biopsy is particularly valuable for “Genomic Staging” and for assessing tumor heterogeneity. A single tissue biopsy may miss mutations present in other parts of the cancer or in metastatic sites. Liquid biopsy captures a composite genetic picture of all tumor deposits in the body, providing a more comprehensive view of the targetable landscape.
Staging for targeted therapy also involves determining if the identified mutation is a “driver” or a “passenger.” Driver mutations initiate and maintain cancer, while passenger mutations are incidental. Targeted therapies are only effective against drivers. Bioinformatic algorithms are used to interpret NGS data and distinguish pathogenic mutations from benign variants. This “Bio-informatic Staging” classifies the tumor not by its size, but by its dependency on specific pathways.
Furthermore, staging involves assessing the presence of co-mutations that might confer resistance. For example, in colorectal cancer, an EGFR inhibitor will not work if there is a downstream KRAS mutation, even if EGFR is overexpressed. Therefore, the “diagnosis” involves a complete mutational workup to rule out resistance pathways before initiating therapy.
Before initiating targeted therapy, a systemic evaluation is required to ensure the patient can tolerate the specific pathway inhibition. For example, before starting a VEGF inhibitor, the patient’s cardiovascular system must be assessed for uncontrolled hypertension or recent clotting events. Before beginning a HER2 inhibitor, cardiac function is evaluated. This “Physiological Staging” ensures that the targeted mechanism will not destabilize the patient’s baseline health.
The complexity of genomic data has led to the creation of the Molecular Tumor Board. This is a multidisciplinary meeting involving oncologists, pathologists, geneticists, and bioinformaticians. They review the NGS reports, interpret the significance of variants of unknown significance (VUS), and match the patient’s unique genetic profile with approved therapies or available clinical trials. This collaborative diagnostic process ensures that the precision medicine promise is realized for each patient.
Send us all your questions or requests, and our expert team will assist you.
A companion diagnostic is a specific medical test developed in parallel with a targeted drug. It is required to identify which patients will benefit from that particular drug. For example, the HER2 test is the companion diagnostic for the drug Trastuzumab. If the test is negative, the drug is not prescribed because it will not work.
Next-Generation Sequencing (NGS) is a technology that enables doctors to scan a tumor’s DNA for mutations in hundreds of genes simultaneously, rather than testing them one by one. This provides a comprehensive “genetic fingerprint” of the cancer, revealing multiple potential treatment targets and helping identify rare mutations for which therapies are available.
Cancers can evolve and change over time, especially after exposure to treatment. The genetic mutations driving the tumor when it returns (recurrence) might be different from when it was first diagnosed. A new biopsy allows doctors to analyze the tumor’s current genetic profile to determine whether new targets have emerged or resistance mutations have developed.
“Wild Type” refers to a gene that does not have mutations; it is the standard, natural version of the gene. For example, if a tumor is “KRAS Wild Type,” it means the KRAS gene is normal. This is often good news for specific treatments (like EGFR inhibitors in colon cancer), which only work if KRAS is normal (Wild Type).
Liquid biopsy is becoming increasingly powerful, but it has not yet entirely replaced tissue biopsy. While it is excellent for detecting mutations and monitoring treatment, a tissue biopsy is often still needed for the initial diagnosis to examine the cells’ shape and structure (histology) and to obtain enough material for extensive testing if the amount of DNA in the blood is too low.
Many people can live with stage 4 cancer for months without obvious signs. Advanced cancers often cause vague symptoms. These symptoms are often mistaken for
Breast cancer diagnosis has changed a lot with new genetic tests. Now, we can give treatments that fit each patient’s genes. The signature test for
Breast cancer diagnosis and treatment rely on specific tumor markers. At Liv Hospital, we focus on three key markers: estrogen receptor (ER), progesterone receptor (PR),
Explore ivermectin cancer clinical trials. Get amazing news on scary treatments and find powerful, vital hope for new rectal therapies. We are seeing a big
When chemotherapy stops working for multiple myeloma, patients face a tough challenge. The disease starts to grow again because it has become resistant. This can
Neuroendocrine tumors (NETs) have long been tough to treat. But, new hope has arrived with the FDA’s approval of cabozantinib, a targeted therapy. This is
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
